Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD November 1, 2010 By Bio-Medicine.Org ‘/>”/> SOURCE